
Low-Grade Astrocytoma: Mutations That Guide Care
Slow-growing grade I and II brain tumors are typed by molecular findings such as IDH, P53 and PML-NTRK2 changes, which inform treatment choice and monitoring.

MD · MBA
Physician specializing in genetic analysis and personalized preventive medicine, and author of Outsmart Your Genes.
Brandon Colby is a physician-expert in the fields of genetic analysis and Personalized Preventive Medicine. He holds an MD from the Mount Sinai School of Medicine, an MBA from Stanford University's Graduate School of Business, and a degree in Genetics from the University of Michigan.
Dr. Colby is the author of the book Outsmart Your Genes and has developed numerous technologies that improve the analysis, interpretation, and actionability of genome sequencing data. He is an Affiliate Specialist of the American College of Medical Genetics and Genomics (ACMG), an Associate of the American College of Preventive Medicine (ACPM), and a member of the National Society of Genetic Counselors (NSGC).
Articles by Brandon Colby, MD are reviewed for accuracy by Sequencing's medical and scientific team. This page is for informational purposes and does not constitute medical advice.

Slow-growing grade I and II brain tumors are typed by molecular findings such as IDH, P53 and PML-NTRK2 changes, which inform treatment choice and monitoring.

Plaque buildup narrows arteries, and research points to markers such as the Sle1 interval and CD36 polymorphisms as contributors to inherited atherosclerosis risk.

Speech can be hard to follow even when outer hair cells work normally. OAE and ABR results, plus OTOF or GJB2 findings, inform hearing aid and cochlear implant choices.

Abnormal long bone development and growth delay can be the first clue to APS-1 in a child; dental enamel findings and AIRE sequencing bring the diagnosis forward.

No sperm in the semen affects about 1% of men. Semen analysis confirms it, while chromosome studies and gene panels link RNF212 and STAG3 to meiotic arrest.

Discover the importance of genetic testing in diagnosing and treating B Lymphoblastic Leukemia Lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1).

A PCM1-JAK2 fusion gene turns up in some cases of this aggressive B-cell blood cancer, and a case study reports a response to the JAK2 inhibitor ruxolitinib.

The Philadelphia chromosome fuses BCR and ABL1, and cytogenetics, FISH and PCR confirm it, guide targeted therapy and track fusion levels during treatment.